Last reviewed · How we verify
deferiprone matching placebo tablets
Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage.
Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage. Used for Transfusion-dependent iron overload in patients with chronic anemias (e.g., thalassemia major, sickle cell disease), Iron overload in patients with myelodysplastic syndromes.
At a glance
| Generic name | deferiprone matching placebo tablets |
|---|---|
| Also known as | Placebo |
| Sponsor | ApoPharma |
| Drug class | Iron chelator |
| Target | Ferric iron (Fe³⁺) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Deferiprone is a bidentate chelating agent that forms stable complexes with ferric iron (Fe³⁺), facilitating its urinary and fecal excretion. By reducing labile iron pools and preventing iron-catalyzed free radical formation, it mitigates oxidative damage to organs in patients with chronic iron overload. This mechanism is particularly important in transfusion-dependent anemias where repeated blood transfusions lead to pathological iron accumulation.
Approved indications
- Transfusion-dependent iron overload in patients with chronic anemias (e.g., thalassemia major, sickle cell disease)
- Iron overload in patients with myelodysplastic syndromes
Common side effects
- Agranulocytosis
- Neutropenia
- Gastrointestinal disturbances (nausea, vomiting, abdominal pain)
- Arthralgia and arthritis
- Elevated liver enzymes
Key clinical trials
- Deferiprone to Delay Dementia (The 3D Study) (PHASE2)
- Study of Parkinson's Early Stage With Deferiprone (PHASE2)
- Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent (PHASE3)
- Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- deferiprone matching placebo tablets CI brief — competitive landscape report
- deferiprone matching placebo tablets updates RSS · CI watch RSS
- ApoPharma portfolio CI